Introduction
============

The first clinically applicable images of the prostate obtained through transrectal ultrasonography (TRUS) were described in 1967 by Watanabe et al.[@b1-ppa-9-1207] Because ultrasound technology has become more refined over the years, the use of TRUS to evaluate prostatic disease has increased. By the mid-1980s, the 7 MHz ultrasound probe, which clearly delineates the architecture of the prostate, had become a standard diagnostic instrument.[@b2-ppa-9-1207] TRUS can be used to detect prostate abnormalities such as benign prostatic hyperplasia, carcinoma of the prostate, prostatitis, prostatic abscess, and prostatic calculi.[@b3-ppa-9-1207] However, a TRUS examination of the prostate is uncomfortable,[@b4-ppa-9-1207] and some patients at Chang Gung Memorial Hospital have claimed that they experienced severe pain when receiving this invasive procedure. Although the degree of and factors influencing pain during TRUS-guided biopsy have been discussed in the literature,[@b5-ppa-9-1207]--[@b7-ppa-9-1207] based on our research, no study has focused on the pain experienced by patients receiving TRUS of the prostate. The purpose of this study was to determine the manner in which patients experience the pain, and to identify the clinical parameters influencing the pain during a TRUS examination.

Materials and methods
=====================

This study was approved by the Institutional Review Board at Chang Gung Memorial Hospital, Taiwan. Records were obtained from a prospective database for male patients who received TRUS of the prostate in the outpatient department from January 2014 to June 2014. The patients underwent a detailed medical history review and physical examination. The patient's age, body mass index, prostate-specific antigen level, previous anal operative history, and TRUS experience were recorded. When routine digital rectal examinations were performed, the anus was carefully inspected and the presence of external hemorrhoids was recorded. Patients with dementia, disabilities that interfered with verbal communication or neurological diseases that potentially influenced pain assessment, as well as patients who had prostatitis or who had received transurethral resection of the prostate were excluded. A total of 498 patients were enrolled in the study.

The patients were randomized into two groups according to medical chart number (odd, group 1; even, group 2). The group 1 patients received the TRUS examination according to the routine procedure of the hospital. By contrast, the group 2 patients received a detailed explanation of the examination procedure immediately before the examination began. In addition, a monitor was placed next to them, enabling them to observe the real-time images during the entire examination. Transrectal ultrasound was performed on the patients by a single urologist using an ultrasound machine (Prosound Alpha 6, Hitachi Ltd., Tokyo, Japan) fitted with a 7.5 MHz biplanar transrectal probe. The prostate volume was measured using the ellipse formula (sagittal length × width × height ×0.52). Whether the patients had stool stored in the rectum that interfered with the image quality ([Figure 1](#f1-ppa-9-1207){ref-type="fig"}) was recorded. Immediately following the examination, the patients completed a visual analog scale (VAS) questionnaire, evaluating the pain experienced during the TRUS on a scale of 0--10. After the patients rated the pain by marking a line to indicate pain level, a rounding method was used to obtain an integer.

The pain score distribution was examined using the Kolmogorov--Smirnov test. The *χ*^2^ test was applied to test qualitative data, and the Mann--Whitney *U*-test was used to test numerical variables. All aforementioned variables were analyzed through linear regression analysis to identify the independent factors influencing the pain experienced during the procedure.

Results
=======

The clinical characteristics of the patients are summarized in [Table 1](#t1-ppa-9-1207){ref-type="table"}. The median patient age, prostate volume, and mean pain score was 63 years (range: 43--87), 32.40 g (range: 10.3--162.00), and 2.87 (range: 0--9), respectively. The distribution of the pain score is presented in [Figure 2](#f2-ppa-9-1207){ref-type="fig"}. No pain (VAS =0) was reported by 53 patients (10.64%), mild pain (VAS =1--3) was described by 318 patients (63.86%), and moderate pain (VAS =4--5) was indicated by 107 (21.49%) patients. However, 60 patients (12.05%) reported experiencing severe pain (VAS =6--10) during the examination. The normal distribution of this result was confirmed through the Kolmogorov--Smirnov test ([Figure 3](#f3-ppa-9-1207){ref-type="fig"}).

When the patients were further subgrouped into two groups: VAS ≤3 and VAS ≥4, as shown in [Table 2](#t2-ppa-9-1207){ref-type="table"}, we found that the patients who indicated VAS scores ≥4 were younger (63.04 vs 65.79, *P*=0.0293), had a larger prostate volume (43.04 g vs 37.41 g, *P*=0.0161), and longer prostate sagittal length (4.69 cm vs 4.56 cm, *P*=0.0415). The data also revealed that a lower percentage of patients whose VAS scores were ≥4 had TRUS experience (13.33% vs 23.85%, *P*=0.0427) and were randomly assigned to group 2 (34.91% vs 60.48%, *P*\<0.0001), compared with patients with VAS scores of ≤3. By contrast, a higher percentage of patients with VAS scores of ≥4 had external hemorrhoids (59.09% vs 26.67%, *P*\<0.0001), anal surgical experience (31.63% vs 6.96%, *P*\<0.0001), and image artifact caused by stool (22.85% vs 11.79%, *P*=0.0068), as shown in [Table 3](#t3-ppa-9-1207){ref-type="table"}.

The group 2 patients had lower VAS scores than group 1 patients (2.62 vs 3.09, *P*=0.002), as shown in [Figure 4](#f4-ppa-9-1207){ref-type="fig"}. In other words, the patients who received a detailed explanation of the procedure and were allowed to observe real-time images experienced less pain compared with the patients who did not.

Clinical parameters associated with TRUS that influenced VAS scores were analyzed ([Table 4](#t4-ppa-9-1207){ref-type="table"}). Multivariate analysis revealed that the prostate sagittal length was the continuous variable influencing the level of pain. Assignment to group 2 and TRUS experience were negatively associated with the VAS score, whereas external hemorrhoids, anal surgical history, and image artifact caused by stool were independent factors that increased the VAS score.

Discussion
==========

The VAS is a simple assessment tool consisting of a 10 cm line with 0 on one end and 10 on the other.[@b8-ppa-9-1207] Patients rate their pain by placing a mark on the line that corresponds to their current level of pain. The scale can be used as a baseline assessment of pain and to evaluate treatment effectiveness.[@b8-ppa-9-1207] This scale has been widely used in many fields of pain research because it is easy to understand, requires less than 1 minute to complete, and has high validity and reliability.[@b9-ppa-9-1207] Therefore, we applied the VAS in our study. Evaluating the degree of pain by using VAS and exploring the factors influencing pain during TRUS-guided biopsy have been discussed in the literature.[@b5-ppa-9-1207]--[@b7-ppa-9-1207] However, based on our research, no study has focused on the pain experienced by the patients receiving TRUS of the prostate. Although the examination is considered an easy procedure by urologists and requires no local anesthesia, some patients claim to have experienced severe pain during the examination. Therefore, we focused on determining the pain scale distribution of the patients and identifying the factors influencing the pain. Our data revealed that the pain scores experienced by the patients were in a normal distribution, and the mean VAS score was only 2.87. This indicated that most of the patients tolerated the pain well and required no anesthesia during the procedure.

Our study revealed that patients with VAS scores of ≥4 were younger than the patients with VAS scores of ≤3 (63.04 vs 65.79, *P*=0.0293). Although multivariate analysis showed that the age was not a strong factor influencing the pain (*P*=0.0671; [Table 4](#t4-ppa-9-1207){ref-type="table"}), we maintain that age plays an influential role. Philips et al[@b10-ppa-9-1207] and Rodriguez et al[@b11-ppa-9-1207] have reported that older patients can tolerate pain more during a TRUS-guided prostate biopsy because of a relatively low anal resting tone. The internal anal sphincter provides approximately 60%--70% of the anal resting tone, whereas the external anal sphincter is responsible for 20%--30%; the remaining 10%--15% is attributed to expansion of the anal cushions, call hemorrhoids.[@b12-ppa-9-1207]--[@b15-ppa-9-1207] Young patients have a relatively high resting anal tone and low anorectal compliance during probe insertion and withdrawal.[@b10-ppa-9-1207]--[@b11-ppa-9-1207] Consequently, younger patients experience more pain during the procedure. Prostate configuration also played a crucial role in the pain during TRUS. Our results revealed that the prostate sagittal length, rather than the prostate volume, affected the pain level. Patients who had a longer prostate sagittal length experienced more pain because when measuring the prostate volume, the probe of the ultrasonography had to be inserted deeper in the rectum, causing more discomfort.

Patients with external hemorrhoids accounted for approximately 33.33% of the entire study population. Hemorrhoids are categorized as external hemorrhoids (distal to the dentate line), internal hemorrhoids (proximal to the dentate line), and mixed hemorrhoids (both proximal and distal). External hemorrhoids are more sensitive to pain, itching, and irritation than are internal hemorrhoids located proximal to the dental line.[@b16-ppa-9-1207] During the TRUS examination, the external hemorrhoids of patients are irritated and are painful. According to our analysis, a higher VAS score was reported by patients with external hemorrhoids, which was an independent factor influencing the pain ([Table 4](#t4-ppa-9-1207){ref-type="table"}). In addition, patients who had anal surgical history also reported a higher degree of pain during TRUS examination. Delayed anal scar tissue, fibrosis, asymptomatic stenosis, or even symptomatic stricture may occur after anal surgical procedures. The incidence of late anal stenosis is not too low and occurs in 4%--5% of patients receiving hemorrhoidectomy.[@b17-ppa-9-1207] A previous study reported that fistulectomy can also induce anal fibrosis.[@b18-ppa-9-1207] Although none of our patients mentioned having the aforementioned surgical complications, we determined that an anal surgical history reduced the compliance of the anal sphincter and, consequently, caused more pain during the probe insertion and withdrawal. Therefore, we suggest using a digital finger insertion with ample lubricant to rinse the dry anal canal, gradually dilating the anal sphincter to prevent anal sphincter spasms. The probe can be inserted slowly and gently after the resting anal tone decreases. Using this technique enables reducing the pain experienced during a TRUS examination by patients with external hemorrhoids or anal surgical history. Our study also revealed that patients experienced more pain when they had stool stored in the rectum that caused image artifact, possibly because the examiner had to obtain a higher quality image by shifting and adjusting the ultrasound probe position in the rectum. Therefore, we suggest that patients who have chronic constipation receive an enema before the procedure.

Czarnecki et al mentioned that pain is based on patient perceptions, which may be influenced by interrelated factors including the patient's emotional and psychological state, level of anxiety, previous pain experience, understanding of the procedure, and medical condition and environmental factors.[@b19-ppa-9-1207] This may explain why the patients who had previous TRUS experience experienced less pain during the procedure. Furthermore, explaining the examination and allowing patients to observe real-time images during the procedure reduced patient anxiety; thus, they experienced less pain. The study of Tarhan et al also revealed that video-based education about the procedure of TRUS biopsy can diminish patient anxiety.[@b20-ppa-9-1207] Therefore, we suggest that a detailed explanation and the ability to observe real-time images of the procedure can significantly reduce the pain of an anxious patient.

There were some flaws and limitations in our study that are worth mentioning. First, some of the patients who received the examination potentially had prostate cancer. We did not further discuss whether prostate cancer would affect the degree of pain experienced by the patients. Second, although our study confirmed that anal surgical history was one of the independent factors influencing the pain associated with TRUS, some of the given history mainly relied on self-reporting rather than an accurate medical chart review. We were unable to understand how the pain associated with TRUS was affected by different anal surgical procedures, for example, hemorrhoidectomy, hemorrhoid ligation, fistulectomy, or fistulotomy. Last but not least, the diagnosis of external hemorrhoids was made by the inspection of an urologist rather than an anorectal specialist. As a result, the high incidence of external hemorrhoids among our patients was questionable.

Conclusion
==========

Although a TRUS examination is uncomfortable for patients, we revealed that most of the study patients tolerated the pain and required no anesthesia during the procedure. However, 21.49% and 12.05% of the patients reported moderate pain and severe pain, respectively. Our study identified various independent factors influencing the pain associated with TRUS: prostate sagittal length, previous TRUS experience, external hemorrhoids, anal surgical history, and stool accumulation in the rectum. The aforementioned methods enable reducing discomfort. Furthermore, alleviating patient anxiety by providing a detailed explanation before the procedure and allowing patients to observe real-time images can reduce the pain.
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![Image shows artifact caused by stool stored in the rectum and interfered with the image quality. The examiner cannot easily measure the prostate sagittal length.](ppa-9-1207Fig1){#f1-ppa-9-1207}

![Distribution of pain score.\
**Abbreviation:** VAS, visual analog scale.](ppa-9-1207Fig2){#f2-ppa-9-1207}

![Kolmogorov--Smirnov test results showing that the pain score was normally distributed.](ppa-9-1207Fig3){#f3-ppa-9-1207}

![Significantly lower pain scores of group 2 patients compared with those of group 1 patients.\
**Abbreviation:** VAS, visual analog scale.](ppa-9-1207Fig4){#f4-ppa-9-1207}

###### 

Characteristics of the study population

  Variable (number =498)                  n (range)
  --------------------------------------- ----------------------
  Median age (years)                      63 (43--87)
  Median BMI                              24.98 (16.8--47.06)
  Median PSA (ng/mL)                      5.03 (0.1--398.7)
  Median prostate volume (mL)             32.40 (10.3--162.00)
  Median prostatic sagittal length (cm)   4.50 (2.42--7.50)
  Mean pain score (VAS)                   2.87±2.02 (0--9)

**Abbreviations:** BMI, body mass index; PSA, prostate-specific antigen; VAS, visual analog scale.

###### 

Comparison of patients' numerical variables between pain score ≤3 and pain score ≥4

  Characteristics                 Pain score ≤3 mean ± SD   Pain score ≥4 mean ± SD   *P*-value
  ------------------------------- ------------------------- ------------------------- ---------------------------------------------------
  Age (years)                     65.79±10.92               63.04±11.67               0.0293[\*](#tfn3-ppa-9-1207){ref-type="table-fn"}
  BMI                             25.11±3.86                25.20±3.76                0.9314
  Prostate volume (gm)            37.41±20.39               43.04±24.45               0.0161[\*](#tfn3-ppa-9-1207){ref-type="table-fn"}
  Prostate sagittal length (cm)   4.56±0.78                 4.69±0.94                 0.0415[\*](#tfn3-ppa-9-1207){ref-type="table-fn"}
  PSA (ng/mL)                     3.24±2.17                 4.85±3.82                 0.8216

**Notes:** Comparisons were made using Mann--Whitney *U*-test.

Indicates significant difference.

**Abbreviations:** BMI, body mass index; PSA, prostate-specific antigen; SD, standard deviation.

###### 

Comparison of patients' qualitative variables between pain score ≤3 and pain score ≥4

  Characteristics                Pain score ≤3 (%)   Pain score ≤4 (%)   *P*-value
  ------------------------------ ------------------- ------------------- -----------------------------------------------------
  Previous TRUS experience (%)   23.85%              13.33%              0.0427[\*](#tfn6-ppa-9-1207){ref-type="table-fn"}
  Group 2 (%)                    60.48%              34.91%              \<0.0001[\*](#tfn6-ppa-9-1207){ref-type="table-fn"}
  External hemorrhoids (%)       26.67%              59.09%              \<0.0001[\*](#tfn6-ppa-9-1207){ref-type="table-fn"}
  Prostate calcification (%)     22.11%              36.19%              0.0893
  Previous anal operation (%)    6.96%               31.63%              \<0.0001[\*](#tfn6-ppa-9-1207){ref-type="table-fn"}
  Stool artifact (%)             11.79%              22.85%              0.0068[\*](#tfn6-ppa-9-1207){ref-type="table-fn"}

**Notes:** Comparisons were made using *χ*^2^ test.

Indicates significant difference.

**Abbreviation:** TRUS, transrectal ultrasound of the prostate.

###### 

Multivariate analysis for the pain associated with TRUS using linear regression analysis

  Variable                                                                 β            SE (β)    *P*-value
  ------------------------------------------------------------------------ ------------ --------- -----------------------------------------------------
  Age (continuous variable)                                                −0.01381     0.0075    0.0671
  BMI (continuous variable)                                                −1.001942    0.0209    0.9258
  Prostate volume (continuous variable)                                    −0.00131     0.0020    0.6571
  Prostate sagittal length (continuous variable)                           0.005547     0.0021    0.0072[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}
  PSA (continuous variable)                                                0.00002831   \<0.001   0.717
  Group 2 (vs group 1)                                                     −0.4484      0.1570    0.0045[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}
  Previous TRUS experience (vs absence of previous TRUS experience)        −0.4234      0.1932    0.0289[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}
  External hemorrhoids (vs absence of external hemorrhoids)                1.261        0.1736    \<0.0001[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}
  Previous anal operation history (vs absence of anal operation history)   1.568        0.2476    \<0.0001[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}
  Prostate calcification (vs no calcification)                             0.4528       0.1800    0.1122
  Stool artifact (vs no stool artifact)                                    0.7174       0.2310    0.0021[\*](#tfn8-ppa-9-1207){ref-type="table-fn"}

**Notes:**

Indicates significant difference.

**Abbreviations:** TRUS, transrectal ultrasonography of the prostate; β, regression coefficient; SE, standard error; BMI, body mass index; PSA, prostate-specific antigen; vs, versus.
